vs
Forestar Group Inc.（FOR）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Forestar Group Inc.的季度营收约是Orthofix Medical Inc.的1.2倍（$273.0M vs $219.9M），Forestar Group Inc.净利率更高（5.6% vs -1.0%，领先6.7%），Forestar Group Inc.同比增速更快（9.0% vs 2.0%），Orthofix Medical Inc.自由现金流更多（$16.8M vs $-157.1M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs -9.6%）
福雷斯特集团是一家住宅地块开发企业，总部位于得克萨斯州阿灵顿，业务覆盖美国21个州的51个市场。截至2020年12月31日的12个月内，该公司交付了11518块住宅地块，目前在纽约证券交易所上市，自2002年起就是美国规模最大的住宅建筑商D.R. Horton的控股子公司。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
FOR vs OFIX — 直观对比
营收规模更大
FOR
是对方的1.2倍
$219.9M
营收增速更快
FOR
高出7.1%
2.0%
净利率更高
FOR
高出6.7%
-1.0%
自由现金流更多
OFIX
多$173.9M
$-157.1M
两年增速更快
OFIX
近两年复合增速
-9.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $273.0M | $219.9M |
| 净利润 | $15.4M | $-2.2M |
| 毛利率 | 20.1% | 71.1% |
| 营业利润率 | 7.6% | 0.2% |
| 净利率 | 5.6% | -1.0% |
| 营收同比 | 9.0% | 2.0% |
| 净利润同比 | -6.7% | 92.4% |
| 每股收益（稀释后） | $0.30 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FOROFIX
| Q4 25 | $273.0M | $219.9M | ||
| Q3 25 | $670.5M | $205.6M | ||
| Q2 25 | $390.5M | $203.1M | ||
| Q1 25 | $351.0M | $193.6M | ||
| Q4 24 | $250.4M | $215.7M | ||
| Q3 24 | $551.3M | $196.6M | ||
| Q2 24 | $318.4M | $198.6M | ||
| Q1 24 | $333.8M | $188.6M |
净利润FOROFIX
| Q4 25 | $15.4M | $-2.2M | ||
| Q3 25 | $86.9M | $-22.8M | ||
| Q2 25 | $32.9M | $-14.1M | ||
| Q1 25 | $31.6M | $-53.1M | ||
| Q4 24 | $16.5M | $-29.1M | ||
| Q3 24 | $81.5M | $-27.4M | ||
| Q2 24 | $38.7M | $-33.4M | ||
| Q1 24 | $45.0M | $-36.0M |
毛利率FOROFIX
| Q4 25 | 20.1% | 71.1% | ||
| Q3 25 | 22.3% | 72.2% | ||
| Q2 25 | 20.4% | 68.7% | ||
| Q1 25 | 22.6% | 62.8% | ||
| Q4 24 | 22.0% | 69.0% | ||
| Q3 24 | 23.9% | 68.7% | ||
| Q2 24 | 22.5% | 67.8% | ||
| Q1 24 | 24.9% | 67.5% |
营业利润率FOROFIX
| Q4 25 | 7.6% | 0.2% | ||
| Q3 25 | 16.9% | -8.3% | ||
| Q2 25 | 11.2% | -7.9% | ||
| Q1 25 | 11.6% | -25.2% | ||
| Q4 24 | 8.7% | -5.3% | ||
| Q3 24 | 19.7% | -9.6% | ||
| Q2 24 | 16.2% | -12.5% | ||
| Q1 24 | 17.6% | -15.6% |
净利率FOROFIX
| Q4 25 | 5.6% | -1.0% | ||
| Q3 25 | 13.0% | -11.1% | ||
| Q2 25 | 8.4% | -6.9% | ||
| Q1 25 | 9.0% | -27.4% | ||
| Q4 24 | 6.6% | -13.5% | ||
| Q3 24 | 14.8% | -13.9% | ||
| Q2 24 | 12.2% | -16.8% | ||
| Q1 24 | 13.5% | -19.1% |
每股收益（稀释后）FOROFIX
| Q4 25 | $0.30 | $-0.05 | ||
| Q3 25 | $1.70 | $-0.57 | ||
| Q2 25 | $0.65 | $-0.36 | ||
| Q1 25 | $0.62 | $-1.35 | ||
| Q4 24 | $0.32 | $-0.76 | ||
| Q3 24 | $1.59 | $-0.71 | ||
| Q2 24 | $0.76 | $-0.88 | ||
| Q1 24 | $0.89 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $211.7M | $82.0M |
| 总债务越低越好 | $793.2M | — |
| 股东权益账面价值 | $1.8B | $450.0M |
| 总资产 | $3.2B | $850.6M |
| 负债/权益比越低杠杆越低 | 0.44× | — |
8季度趋势，按日历期对齐
现金及短期投资FOROFIX
| Q4 25 | $211.7M | $82.0M | ||
| Q3 25 | $379.2M | $62.9M | ||
| Q2 25 | $189.2M | $65.6M | ||
| Q1 25 | $174.3M | $58.0M | ||
| Q4 24 | $132.0M | $83.2M | ||
| Q3 24 | $481.2M | $30.1M | ||
| Q2 24 | $359.2M | $26.4M | ||
| Q1 24 | $416.2M | $27.0M |
总债务FOROFIX
| Q4 25 | $793.2M | — | ||
| Q3 25 | $802.7M | $157.2M | ||
| Q2 25 | $872.8M | $157.0M | ||
| Q1 25 | $872.5M | $156.9M | ||
| Q4 24 | $806.8M | $157.0M | ||
| Q3 24 | $706.4M | $118.5M | ||
| Q2 24 | $706.1M | $118.0M | ||
| Q1 24 | $705.7M | $118.2M |
股东权益FOROFIX
| Q4 25 | $1.8B | $450.0M | ||
| Q3 25 | $1.8B | $442.5M | ||
| Q2 25 | $1.7B | $458.3M | ||
| Q1 25 | $1.6B | $458.3M | ||
| Q4 24 | $1.6B | $503.1M | ||
| Q3 24 | $1.6B | $525.9M | ||
| Q2 24 | $1.5B | $546.0M | ||
| Q1 24 | $1.5B | $570.3M |
总资产FOROFIX
| Q4 25 | $3.2B | $850.6M | ||
| Q3 25 | $3.1B | $832.6M | ||
| Q2 25 | $3.1B | $837.2M | ||
| Q1 25 | $3.0B | $823.1M | ||
| Q4 24 | $3.0B | $893.3M | ||
| Q3 24 | $2.8B | $867.9M | ||
| Q2 24 | $2.7B | $882.0M | ||
| Q1 24 | $2.6B | $906.0M |
负债/权益比FOROFIX
| Q4 25 | 0.44× | — | ||
| Q3 25 | 0.45× | 0.36× | ||
| Q2 25 | 0.52× | 0.34× | ||
| Q1 25 | 0.53× | 0.34× | ||
| Q4 24 | 0.50× | 0.31× | ||
| Q3 24 | 0.44× | 0.23× | ||
| Q2 24 | 0.47× | 0.22× | ||
| Q1 24 | 0.48× | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-157.0M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $-157.1M | $16.8M |
| 自由现金流率自由现金流/营收 | -57.5% | 7.6% |
| 资本支出强度资本支出/营收 | 0.0% | 4.9% |
| 现金转化率经营现金流/净利润 | -10.19× | — |
| 过去12个月自由现金流最近4个季度 | $93.0M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流FOROFIX
| Q4 25 | $-157.0M | $27.7M | ||
| Q3 25 | $256.3M | $12.4M | ||
| Q2 25 | $15.8M | $11.6M | ||
| Q1 25 | $-19.8M | $-18.4M | ||
| Q4 24 | $-450.0M | $23.7M | ||
| Q3 24 | $119.2M | $11.7M | ||
| Q2 24 | $-61.7M | $9.0M | ||
| Q1 24 | $-59.2M | $-18.6M |
自由现金流FOROFIX
| Q4 25 | $-157.1M | $16.8M | ||
| Q3 25 | $255.6M | $2.5M | ||
| Q2 25 | $15.0M | $4.5M | ||
| Q1 25 | $-20.5M | $-25.1M | ||
| Q4 24 | — | $15.2M | ||
| Q3 24 | $118.4M | $6.3M | ||
| Q2 24 | $-62.3M | $-360.0K | ||
| Q1 24 | $-59.8M | $-29.1M |
自由现金流率FOROFIX
| Q4 25 | -57.5% | 7.6% | ||
| Q3 25 | 38.1% | 1.2% | ||
| Q2 25 | 3.8% | 2.2% | ||
| Q1 25 | -5.8% | -13.0% | ||
| Q4 24 | — | 7.0% | ||
| Q3 24 | 21.5% | 3.2% | ||
| Q2 24 | -19.6% | -0.2% | ||
| Q1 24 | -17.9% | -15.4% |
资本支出强度FOROFIX
| Q4 25 | 0.0% | 4.9% | ||
| Q3 25 | 0.1% | 4.8% | ||
| Q2 25 | 0.2% | 3.5% | ||
| Q1 25 | 0.2% | 3.5% | ||
| Q4 24 | 0.0% | 4.0% | ||
| Q3 24 | 0.1% | 2.7% | ||
| Q2 24 | 0.2% | 4.7% | ||
| Q1 24 | 0.2% | 5.6% |
现金转化率FOROFIX
| Q4 25 | -10.19× | — | ||
| Q3 25 | 2.95× | — | ||
| Q2 25 | 0.48× | — | ||
| Q1 25 | -0.63× | — | ||
| Q4 24 | -27.27× | — | ||
| Q3 24 | 1.46× | — | ||
| Q2 24 | -1.59× | — | ||
| Q1 24 | -1.32× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FOR
| D.R.Horton Inc. | $183.8M | 67% |
| Other | $89.2M | 33% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
